Constipation is a common gastrointestinal condition affecting people across age groups and is increasingly associated with sedentary lifestyles, dietary patterns, medication use, and aging. The growing burden of chronic and recurrent symptoms is creating greater demand for effective therapeutic interventions.

The Constipation Treatment Market was valued at US$9.93 billion in 2023 and is projected to reach US$17.69 billion by 2031, registering a CAGR of 6.0% during 2024-2031. Rising prevalence, increasing product approvals, and the development of innovative therapies for chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC) are supporting industry expansion.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00005408

Rising Prevalence of Constipation Drives Growth

The increasing prevalence of constipation is a major factor contributing to demand for treatment options. Approximately 16% of the global population experiences constipation, while the prevalence reached 33.5% in 2023 according to the referenced analysis. Poor dietary habits, insufficient physical activity, reduced bowel motility associated with aging, and certain medications can contribute to the condition. Constipation can also negatively affect quality of life and create psychological and social burdens, particularly among patients experiencing chronic symptoms.

The growing geriatric population represents another important growth factor. Older adults are more susceptible to constipation because of physiological changes, reduced mobility, dietary factors, and the use of medications that can affect gastrointestinal function. At the same time, increasing awareness of gastrointestinal health is encouraging patients to seek diagnosis and treatment earlier.

Product Approvals and Innovative Therapies Create Opportunities

Increasing product launches and regulatory approvals are strengthening treatment availability. Pharmaceutical companies are developing therapies designed to address specific mechanisms underlying constipation, providing alternatives for patients who do not achieve adequate relief through conventional laxatives.

Laxatives remain an established treatment option, particularly for acute and mild constipation. However, the therapeutic landscape has expanded to include chloride channel activators, GC-C agonists, peripherally acting mu-opioid receptor antagonists, and 5-HT4 receptor agonists. Drugs such as lubiprostone, linaclotide, and prucalopride have contributed to the development of targeted treatment approaches.

The approval and introduction of new therapies are also creating opportunities for companies to address unmet needs. In 2021, the US Food and Drug Administration approved generic linaclotide capsules for IBS-C and chronic idiopathic constipation. In 2022, Ardelyx launched IBSRELA, an NHE3 inhibitor indicated for adults with IBS-C. The same year, the FDA approved Vibrant Gastro's Vibrant system for chronic constipation. Such developments demonstrate continued innovation across pharmacological and nonpharmacological treatment approaches.

Segmentation Highlights Therapeutic and Disease Trends

Based on therapeutic, the industry is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists. Laxatives accounted for the largest share in 2023 because of their widespread use, established clinical acceptance, availability, and relatively accessible cost. However, targeted therapies are expected to gain importance as physicians seek more specialized treatment options for chronic conditions.

By disease, chronic idiopathic constipation held the largest share in 2023. The segment benefits from the substantial patient population requiring ongoing management and the availability of prescription and over-the-counter therapies. IBS-C and OIC also represent important areas of therapeutic demand, particularly as gastrointestinal symptoms associated with medications and chronic diseases receive greater clinical attention.

By distribution channel, retail pharmacies dominated in 2023. Their broad geographic accessibility and extensive availability of prescription and over-the-counter products support segment growth. Online pharmacies are also gaining traction because of increasing digital adoption, convenience, home delivery, and expanding access to healthcare products.

Regional Outlook and Competitive Landscape

North America held a leading position in 2023, supported by the high prevalence of constipation, a growing geriatric population, established healthcare infrastructure, and ongoing product development. The US represents a particularly important contributor because of increasing product launches, regulatory approvals, and pharmaceutical research activities. Europe also represents a significant regional market, while Asia Pacific is expected to register the highest CAGR during the forecast period. Growing healthcare expenditure, increasing awareness, expanding pharmaceutical capabilities, and a large patient population are supporting opportunities across countries such as China, India, and Japan.

Key players operating in the Constipation Treatment Market include:

• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.
• Bayer AG
• Mallinckrodt plc
• Sanofi
• AstraZeneca
• Ironwood Pharmaceuticals, Inc.
• Salix Pharmaceuticals, Inc.
• Abbott Laboratories
• Cosmo Pharmaceuticals N.V.
• Pfizer Inc.
• Boehringer Ingelheim GmbH
• Janssen Pharmaceutical Companies
• Synergy Pharmaceuticals, Inc.

Competition is increasingly centered on therapeutic innovation, product approvals, strategic collaborations, geographic expansion, and development of treatments addressing patients who remain inadequately controlled with conventional therapies.

Future Outlook

Rising disease prevalence, population aging, expanding awareness, and increasing pharmaceutical innovation will remain important growth factors. The development of mechanism-specific therapies and treatments for difficult-to-manage conditions such as IBS-C and OIC is expected to create additional opportunities. Asia Pacific is likely to emerge as a particularly attractive growth region, while North America will continue to benefit from strong pharmaceutical activity and established healthcare infrastructure.

Related Report:

1) Defibrillator Market Key Players and Forecast by 2031

2) Infection Control Market Analysis by Size, Share & Growth 2031

3) Laboratory Water Distiller Market Size, Share & Demand by 2034

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish